When your child is diagnosed with cancer, a blood disease or immune deficiency disorder, finding the right medical team is your first and most important step. Our experienced team sees nearly 7,000 patients each year. At any given time, more than 250 patients are being treated for cancer or blood disorders here. Arkansas Children's Cancer and Blood Disorders Program is the only pediatric cancer treatment program in the state. The large number of children we will serve each year, helps us develop new care and treatments and train future health leaders through our fellowship program.
Arkansas Children's Hospital provides right-sized care for your child. U.S. News & World Report has ranked Arkansas Children's in seven specialties, including Cancer, for 2023-2024. Learn more.
When your child is diagnosed with hemophilia or a bleeding disorder, the experts at the Arkansas Center for Bleeding Disorders work with you and your child to create a care plan that keeps your child healthy while living life to the fullest.
If your newborn or young child has been diagnosed with sickle cell disease, you likely have a lot of questions. The good news is, with the right care, many children with sickle cell live long, healthy lives. Arkansas Children's can diagnose, evaluate and treat children who have sickle cell disease.
The Bone and Soft-tissue Tumor Program at Arkansas Children’s Hospital provides specialty care for children with cancer of the bone, muscle, or connective tissues.
Hypercoagulable conditions are disorders where the blood is more likely to cause blood clots in the blood vessels. Thrombophilia is a medical term we use to describe the blood's increased tendency to clot. There are two types of thrombophilia: inherited thrombophilia and acquired thrombophilia.
Treatment of cHL in children and young adults – evaluation of pembrolizumab in a subgroup with inadequate early response to frontline chemotherapy.
This study will evaluate the use of Difluoromethylornithine (DFMO) as a single agent in patients with high risk medulloblastoma after completing therapy as maintenance therapy with the hopes of preventing relapse.
The purpose of this study is to test the effectiveness of using an investigational agent called DFMO along with etoposide for Neuroblastoma.
This is an open-label, sequential-arm, Phase 1b/2 clinical trial of bempegaldesleukin in combination with nivolumab in pediatric participants with malignancies that are refractory, relapsed, or participants for whom curative treatments are lacking.
A prospective open label, multicenter study to evaluate the feasibility and side effects of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days by mouth difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 twice daily on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia.